Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADDRESS+ open-label extension study of subcutaneous efgartigimod PH20 in pemphigus
MOH_2021-03-17_009846Phase 3Active, not recruiting
- Sponsor
- argenx
- Start
- Mar 2021
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa and ENHANZE in pemphigus vulgaris (PV) and pemphigus foliaceus (PF), sponsored by argenx. Primary endpoint: Safety of continued and repeated treatment with subcutaneous efgartigimod PH20. Started Mar 2021; status: active, not recruiting.
02
Drugs
efgartigimod alfaENHANZE
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on MOH_2021-03-17_009846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-03-17_009846.